New search | Conferencedetail
Print view
 
 

3rd Annual RAS Targeted Drug Development Summit!

Evvnt Promotion / evvnt
-
21.09.2021 - 23.09.2021  Online
Time: 8:00 am - 5:15 pm
 
Conference themes
As promising clinical trial data emerges for KRAS G12C inhibitors and with strong chances of receiving FDA approval this year, the once undruggable RAS family of proteins no longer seem impossible to be cracked. This has undoubtedly resulted in great momentum in the field of oncology to develop RAS targeted therapies that safely, effectively and selectively drug all RAS driven cancers beyond those caused by G12C mutation.
Professional congress organizer (PCO)
Hanson Wade
Notes
Brochure: https://go.evvnt.com/790905-3?pid=4832

Speakers: Gregory Friberg, Vice President Global Development and Oncology Therapeutic Area Head, Amgen, Susan Yang, Adagrasib Medical Lead, Mirati Therapeutics and more
 

Enquiries and Registration:

https://go.evvnt.com/790905-0?pid=4832
Mr. Customer Service
 
Categories
General Medicine
Languages
English
Congress fees
USD 2099.00 - USD 4198.00
Participants expected
1000
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

Hilfswerk AustriaAnästhesie in Entwicklungsländern e. V.Österreichisches Rotes KreuznewTreeÖsterreichische Gesellschaft für Public HealthHelix - Forschung & Beratung WienAGEM - Arbeitsgemeinschaft Ethnologie und MedizinÄrztekammer für Wien